Business Context and Reporting Period
Company: electroCore, Inc. (ECOR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: A bioelectronic technology company focused on non-invasive devices for medical conditions (gammaCore, Quell) and general wellness (Truvaga, TAC-STIM). The company operates as a single segment: Bioelectronic Innovations. It recently acquired NeuroMetrix, Inc. (NURO) in May 2025.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $9,584 | $6,719 |
| Gross Profit | $8,364 | $5,706 |
| Gross Margin | 87.3% | 85.0% |
| Operating Loss | $(5,316) | $(3,822) |
| Net Loss | $(5,271) | $(3,855) |
| Net Loss Per Share (Basic/Diluted) | $(0.59) | $(0.47) |
| Cash & Cash Equivalents | $4,852 | $4,027 |
| Total Cash Position (incl. Marketable Securities) | $8,830 | $11,611 |
| Total Debt (Current + Long-term) | $6,687 | $6,607 |
| Stockholders' Deficit | $(5,688) | $(1,709) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 43% to $9.6 million, driven by higher prescription sales to the U.S. Department of Veterans Affairs (VA), which accounted for 74.8% of revenue, and the inclusion of Quell Fibromyalgia products following the NURO acquisition.
- Expense Increase: Selling, general, and administrative (SG&A) expenses rose $4.1 million to $12.9 million. This was primarily due to $1.6 million in variable sales expenses, $1.2 million in severance costs related to the former CEO's retirement, and increased legal fees.
- Interest Expense: Interest expense surged to $318,000 from $5,000 in the prior year due to the new $7.5 million term loan facility with Avenue Opportunities Fund II.
- Liquidity: Cash and cash equivalents decreased by $2.2 million during the quarter, though the total cash position (including marketable securities) remains at $8.8 million.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Forecasted cash is insufficient to fund operating expenses and capital requirements for the next 12 months without additional financing.
- Capital Resources: The company relies on equity and debt financings. It has an effective $100 million Shelf Registration Statement and an At-The-Market (ATM) facility with $18.8 million remaining. Subsequent to quarter-end, the company raised approximately $1 million via ATM sales and warrant exercises.
- Leadership Transition: The former CEO, Daniel S. Goldberger, retired effective April 1, 2026. The company is navigating a leadership transition under an Interim President and CFO.
- Legal Proceedings: Ongoing patent litigation with UAB Pulsetto regarding non-invasive vagus nerve stimulation technology. Proceedings are stayed for private mediation scheduled for May 2026.
- Regulatory Risk: An unannounced, "for cause" FDA inspection occurred at the company's Rockaway, NJ facility on May 5, 2026. The outcome is uncertain and could impact operations.
- Internal Controls: Disclosure controls were deemed ineffective due to a material weakness in lease accounting identified in the prior year, though remediation is underway.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.8 million cash position against the stated 12-month funding gap and the timeline for potential new equity/debt raises.
- Debt Covenants: Review the specific financial covenants (minimum revenue and cash levels) in the Avenue Loan and Security Agreement to assess default risk.
- Customer Concentration: Monitor the stability of the VA contract, which represents nearly 75% of revenue, and the impact of the Lovell Government Services distribution agreement.
- Legal Exposure: Track the outcome of the Pulsetto litigation and the FDA inspection to assess potential liabilities or operational restrictions.
- Leadership Stability: Assess the impact of the CEO departure and the appointment of interim leadership on strategic execution and employee retention.